Minsheng securities released a research report on January 27, saying that it maintained the recommended rating of Pharmablock Sciences (Nanjing) Inc(300725) (300725. SZ). The reasons for rating mainly include: 1) the income side is affected by the phased epidemic, and the gradual release of new production capacity is expected to drive accelerated growth; 2) The performance of profit side is under pressure due to the increase of expenses and the impact of exchange rate; 3) The company has comprehensively transformed platform cdmo, and the future can be expected. Risk warning: the risk of performance falling short of expectations, new business investment risk and fixed asset investment risk.
AI comments: Pharmablock Sciences (Nanjing) Inc(300725) has received attention from 4 research reports of securities companies in recent month and bought 4.
